Floatz logo

Tucidinostat

Metastatic Malignant Neoplasm In The Colon

Explore 65 assets in Metastatic Malignant Neoplasm In The Colon →
Floatz Rating
CCC52/100
Confidence
Indicative
v0.2
Sponsor
Feng Wang
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT06979908CT.gov
A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer
—Recruiting———
NCT06682247CT.gov
A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer
—Not Yet Recruiting———
NCT06685276CT.gov
Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer
—Recruiting———
NCT05281276CT.gov
Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)
—Terminated———
NCT04724239CT.gov
Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
—Unknown———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Metastatic Malignant Neoplasm In The Colon

AssetSponsorPhaseRating
Tucidinostat (this asset)Feng WangP2CCC · 52
BinimetinibPierre Fabre MedicamentP3BB
IrinotecanOncolytics BiotechP4BB
AfliberceptSanofiP3BB
AdriamycinNorthwell HealthP4B
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, DimerCentre Georges Francois LeclercP2B
DurvalumabUniversity of IowaP2B
FamitinibJiangsu HengRui Medicine Co., Ltd.P3B
VemurafenibFudan UniversityP3B

+42 more in the Metastatic Malignant Neoplasm In The Colon cohort

Other indications for Tucidinostat

IndicationSponsorPhaseRating
Extranodal Nasal NK/T Cell Lymphoma—P4BB · 70
Peripheral T-Cell Lymphoma, Not Otherwise Specified—P4BB · 69
Acute Lymphoblastic Leukemia—P2/3BB · 68

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Tucidinostat in Metastatic Malignant Neoplasm In The Colon. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/tucidinostat-metastatic-malignant-neoplasm-in-the-colon

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →